SAB Biotherapeutics (SABS) Cash from Investing Activities (2021 - 2026)

SAB Biotherapeutics has reported Cash from Investing Activities for 6 years, with the latest figure at -$65.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 1505.4% year-over-year to -$65.6 million; the trailing twelve-month figure through Mar 2026 stood at -$192.0 million (down 897.84% YoY), and the FY2025 full-year result was -$121.7 million, down 917.42% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$65.6 million, down from -$1.7 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $11.2 million in Q2 2024, with the low at -$129.9 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$11.9 million across 5 years, with a median of -$78504.0 in 2022.
• The largest YoY upside for Cash from Investing Activities was 49556.96% in 2024 against a maximum downside of 147126.32% in 2024.
• SAB Biotherapeutics' Cash from Investing Activities stood at -$117754.0 in 2022, then surged by 42.37% to -$67864.0 in 2023, then jumped by 13849.21% to $9.3 million in 2024, then sank by 118.29% to -$1.7 million in 2025, then tumbled by 3747.7% to -$65.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$65.6 million (Q1 2026), -$1.7 million (Q4 2025), and -$129.9 million (Q3 2025), per Business Quant data.